Clinical trials: All Patients Are in the Initial Treatment Phase

B-Cell Acute Lymphoblastic Leukemia

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

• Active, not recruiting
• Age: 1 year to 25 years
• Phase 2

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD…

Trial name

CASSIOPEIA (NCT03876769)

Testing

CTL019

Where

43 sites in United States, Belgium and 9 more

Volunteers

121 people

Sponsor

Novartis Pharmaceuticals